Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in October

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 8,270,000 shares, an increase of 15.8% from the October 15th total of 7,140,000 shares. Approximately 11.4% of the company's stock are short sold. Based on an average daily volume of 463,300 shares, the short-interest ratio is presently 17.9 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd during the 3rd quarter valued at $27,000. XTX Topco Ltd boosted its stake in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock worth $42,000 after acquiring an additional 15,376 shares in the last quarter. SG Americas Securities LLC grew its holdings in Invivyd by 198.6% during the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company's stock valued at $42,000 after purchasing an additional 25,201 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Invivyd in the 2nd quarter valued at $86,000. Finally, Rhumbline Advisers raised its holdings in Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company's stock worth $92,000 after acquiring an additional 82,164 shares during the period. Institutional investors own 70.36% of the company's stock.

Invivyd Stock Down 4.5 %

Invivyd stock traded down $0.04 during mid-day trading on Friday, hitting $0.76. 563,067 shares of the company's stock traded hands, compared to its average volume of 632,977. Invivyd has a one year low of $0.76 and a one year high of $5.20. The firm has a 50 day moving average price of $0.99 and a 200 day moving average price of $1.30. The company has a market cap of $90.19 million, a PE ratio of -0.39 and a beta of 0.65.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.03). The company had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.91 million. On average, analysts expect that Invivyd will post -0.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Invivyd in a research note on Tuesday, October 29th.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.